Rilzabrutinib Reduces Itch, Hives in Chronic Spontaneous Urticaria in Phase 2 Trial
Rilzabrutinib, an oral BTK inhibitor, demonstrates efficacy in reducing itch and disease activity among patients with chronic spontaneous urticaria in phase 2 dose-ranging trial at AAAAI 2024.